This episode digs into the pathophysiology of urticaria vasculitis from anti-C1q to the story of bradykinin.

· Intro 0:11

· In this episode 0:22

· Review of episode 83 1:23

· Listen to previous episode, The Complement System for Dunces 4:09

· Anti-C1q antibodies 6:26

· Lupus, anti-C1q and lupus nephritis 9:33

· What happens when you inject anti-C1q in a mouse? 12:56

· The allergy component: anti-C1q, urticaria and angioedema 17:36

· Bradykinin-mediated angioedema and C1q deficiency 24:20

· What is the kinin kallikrein system? 26:21

· French researchers in 1909: human urine injected in dogs 27:30

· How is this relevant to urticarial vasculitis? 31:08

· SERPING1 gene mutation 31:23

· Summary 32:06

· COPD association with urticarial vasculitis 33:51

· Coming up in episode 85 35:28

· Thanks for listening 35:45

Disclosures: Brown reports no relevant financial disclosures.

We’d love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum.

References:

Busse P, et al. J Allergy Clin Immunol Pract. 2022;doi:10.1016/j.jaip.2021.11.011.

Davis MDP, et al. J Allergy Clin Immunol Pract. 2018;doi:10.1016/j.jaip.2018.05.006.

Dorn JM, et al. Ann Allergy Asthma Immunol. 2023;doi:10.1016/j.anai.2023.06.014.

Marzano AV, et al. J Allergy Clin Immunol. 2022;doi:10.1016/j.jaci.2022.02.007.

Siegert CE, et al. Clin Immunol Immunopathol. 1993;doi:10.1006/clin.1993.1066.

Stojan G, et al. Lupus. 2016;doi:10.1177/0961203316645205.

Venzor J, et al. Clin Rev Allergy Immunol. 2002;doi:10.1385/CRIAI:23:2:201.

Wisnieski JJ, et al. Medicine. 1995;doi:10.1097/00005792-199501000-00003.

Is it an allergy or an autoimmune vasculitis, or a little of both? Find out the story of urticarial vasculitis, how this disease was recognized and eventually sorted out from other types of urticaria.

· Intro 0:12

· In this episode 0:21

· Case study 1:22

· Chronic spontaneous urticaria, hives and nettles 7:57

· Dermatographism and witchcraft? 10:15

· Causes of urticaria 11:17

· Theory of inflammation and histamines 11:40

· Urticaria and treatments with histamines 12:09

· Types of urticaria 13:02

· Mayo Clinic study 13:39

· Chronic urticaria as a manifestation of necrotizing venulitis 16:10

· Connection between types of urticaria and leukocytoclastic vasculitis 20:02

· More case studies 20:38

· What do we know about treatments? 22:23

· In conclusion 24:15

· Coming up in part two 25:08

· Thanks for listening 25:47

Disclosures: Brown reports no relevant financial disclosures.

We’d love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum.

References:

Czarnetzki BM. Int J Dermatol. 1989;doi:10.1111/j.1365-4362.1989.tb01314.x.

Kolkhir P, et al. J Allergy Clin Immunol. 2019;doi:10.1016/j.jaci.2018.09.007.

McDuffie FC, et al. Mayo Clin Proc. 1973;48(5):340-8.

Natbony SF, et al. J Allergy Clin Immunol. 1983;doi:10.1016/0091-6749(83)90096-9.

Soter NA. N Engl J Med. 1977;doi:10.1056/NEJM197706232962505.

What should rheumatologists know about what we've learned about COVID-19 and long COVID in 2023? Hosted by Dr. Leonard Calabrese.

·       Intro 0:11

·       In this episode 0:21

·       2023: current status and controversies 0:35

·       What is going on with COVID-19? 01:53

·       What do we know about vaccine responses? What should we be telling our patients about vaccines in our immunocompromised population? 2:58

·       Lancet Rheumatology MELODY study summary 3:08

·       What about patients within the rheumatic and autoimmune disease space? 4:15

·       Who is immunocompromised and why does it matter? 5:11

·       What is the immunosuppression we are giving them? 6:39

·       What to tell patients about getting vaccinated 8:56

·       Long COVID 10:09

·       What is long COVID? 10:26

·       JAMA Network Open study on prevalence and characteristics associated with post-COVID conditions 14:19

·       In the clinical arena, what should rheumatologists be thinking about? 16:38

·       What about pathogenesis? What do we know about the controversies in this area? 18:58

·       Autoimmunity: COVID-19 and autoimmune response 20:45

·       What about therapies? 22:22

·       The next generation of rheum agents: Immunomodulation with neonatal Fc receptor targeting? 24:40

·       A question for the rheumatology community: do patients with immune mediated diseases get more long COVID than the control population? 25:40

·       In conclusion 27:37

·       Thanks for listening 28:38

Leonard H. Calabrese, DO, is the chief medical editor, Healio Rheumatology, and professor of medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and RJ Fasenmyer chair of clinical immunology at the Cleveland Clinic.

Disclosures: Calabrese reports professional relationships with AbbVie, AstraZeneca, Bristol Myers Squibb, Galvani, Genentech, GlaxoSmithKline, Janssen, Novartis, Regeneron, Sanofi and UCB..

We’d love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum.